Elicio Therapeutics (ELTX) EBT Margin (2020 - 2022)
Elicio Therapeutics' (ELTX) quarterly EBT Margin came in at 1117.76% in Q2 2022, up 226075.0% on a YoY basis from N/an in Q2 2021, and down 27.17% quarter-over-quarter from 878.94% in Q1 2022.
Powered by 
Analysis
Elicio Therapeutics (ELTX) EBT Margin (2020 - 2022) Analysis & Trends
Elicio Therapeutics (ELTX) has reported EBT Margin for 3 consecutive years, with 1117.76% the latest figure, recorded in Q2 2022.
- For the quarter ending Q2 2022, EBT Margin rose 226075.0% year-over-year to 1117.76%; the trailing twelve-month figure through Mar 2023 stood at 4329.56% (down 421515.0% YoY), and the FY2022 full-year result was 1184.92%, down 104608.0% from the prior year.
- EBT Margin fell to 1117.76% in Q2 2022 per ELTX's latest filing, from 878.94% in the prior quarter.
- Across five years, EBT Margin topped out at 56.41% in Q4 2021 and bottomed at 5374.39% in Q1 2021.
- Historically, EBT Margin has averaged 2001.27% across 3 years, with a median of 1426.96% in 2020.
- The sharpest annual moves came in 2021 and 2022: EBT Margin tumbled 392133 bps in 2021, then surged 449545 bps in 2022.
- Over 3 years, EBT Margin stood at 3017.43% in 2020, then surged by 102 bps to 56.41% in 2021, then sank by 2081 bps to 1117.76% in 2022.
- According to Business Quant data, EBT Margin over the past three periods registered 1117.76%, 878.94%, and 56.41% for Q2 2022, Q1 2022, and Q4 2021 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -20,427.46% |
| 10 | Elicio Therapeutics | 40.60 Mn | 17.10 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2022 | -1,117.76% |
| Mar 31, 2022 | -878.94% |
| Dec 31, 2021 | 56.41% |
| Sep 30, 2021 | -1,079.32% |
| Jun 30, 2021 | -3,378.52% |
| Mar 31, 2021 | -5,374.39% |
| Dec 31, 2020 | -3,017.43% |
| Sep 30, 2020 | -1,400.85% |
| Jun 30, 2020 | -2,368.86% |
| Mar 31, 2020 | -1,453.06% |